Sp1293
FROM DIAGNOSIS TO MANAGEMENT IN EOSINOPHILIC ESOPHAGITIS: THE CLINICAL CONSEQUENCES OF A CHRONIC, PROGRESSIVE DISEASE
Date
May 20, 2024
Presenter
Tracks
Related Products
EOSINOPHILIC ESOPHAGITIS: DISCOVER A TREATMENT OPTION FOR YOUR PATIENTS
Take an afternoon break with us to learn about a treatment option for your appropriate patient with eosinophilic esophagitis…
DUPILUMAB IS EFFICACIOUS IN EOSINOPHILIC ESOPHAGITIS REGARDLESS OF PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY-EOE-TREET STUDY
BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…